Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis

Table 4 Subgroup analysis showing disease-specific risk with VDR ApaI polymorphism

Model	Type of disease	N	OR	95% CI	p-val
Allele contrast (A vs. a)	Overall	13	1.05	[0.9282; 1.1931]	0.4259
	ESRD	2	1.31	[1.1454; 1.4996]	0.0001
	NL	6	0.86	[0.7193; 1.0175]	0.0777
	CH	1	1.44	[0.7974; 2.5983]	0.2268
	DN	4	1.06	[0.9361; 1.1997]	0.3589
Recessive model (AA vs. Aa+aa)	Overall	13	1.10	[0.8891; 1.3548]	0.3865
	ESRD	2	1.85	[1.3925; 2.4544]	0.0000
	NL	6	0.77	[0.5591; 1.0553]	0.1035
	CH	1	1.15	[0.4482; 2.9300]	0.7760
	DN	4	1.06	[0.8695; 1.2818]	0.5840
Dominant model (AA+Aa vs. aa)	Overall	13	1.03	[0.8131; 1.3008]	0.8153
	ESRD	2	1.21	[0.7844; 1.8716]	0.3868
	NL	6	0.76	[0.5034; 1.1586]	0.2049
	CH	1	2.13	[0.8380; 5.4311]	0.1120
	DN	4	1.09	[0.8749; 1.3545]	0.4466
Overdominant (Aa vs. AA + aa)	Overall	13	0.99	[0.8143; 1.2066]	0.9300
	ESRD	2	0.91	[0.4290; 1.9490]	0.8167
	NL	6	0.96	[0.6559; 1.3933]	0.8147
	CH	1	1.69	[0.7239; 3.9340]	0.2256
	DN	4	1.03	[0.8660; 1.2221]	0.7472
pairw1 (AA vs. aa)	Overall	13	1.09	[0.8006; 1.4779]	0.5907
	ESRD	2	1.81	[1.3275; 2.4638]	0.0002
	NL	6	0.70	[0.4803; 1.0158]	0.0604
	CH	1	1.89	[0.6130; 5.8330]	0.2677
	DN	4	1.09	[0.8307; 1.4252]	0.5399
pairw2 (AA vs. Aa)	Overall	13	1.10	[0.8709; 1.3854]	0.4280
	ESRD	2	1.74	[0.9540; 3.1683]	0.0709
	NL	6	0.86	[0.5968; 1.2327]	0.4068
	CH	1	0.82	[0.2948; 2.2927]	0.7082
	DN	4	1.02	[0.8306; 1.2477]	0.8635
pairw3 (Aa vs. aa)	Overall	13	1.03	[0.7832; 1.3445]	0.8515
	ESRD	2	1.06	[0.5720; 1.9761]	0.8464
	NL	6	0.79	[0.4507; 1.3857]	0.4113
	CH	1	2.30	[0.8331; 6.3500]	0.1080
	DN	4	1.10	[0.8688; 1.3802]	0.4417

ISSN: 1471-2350